In recent years, Low-dose interleukin 2 (Ld-IL2) therapy has emerged as a promising treatment for a range of autoimmune diseases, including systemic lupus erythematosus (SLE) [1], rheumatoid arthritis (RA) [2], and dermatomyositis (DM) [3]. This evidence concerns the gene IL2 and dermatomyositis.